- Home
- PAI vs VRCA Comparison
PAI vs VRCA Comparison
Compare PAI & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAI | VRCA |
|---|---|---|
| Founded | 1973 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.3M | 112.4M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | PAI | VRCA |
|---|---|---|
| Price | $12.65 | $7.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 25.0K | ★ 147.3K |
| Earning Date | 01-01-0001 | 03-10-2026 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,829,000.00 |
| Revenue This Year | N/A | $372.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 234.73 |
| 52 Week Low | $10.59 | $3.28 |
| 52 Week High | $12.63 | $9.82 |
Technical Indicators
Market Signals| Indicator | PAI | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 60.44 | 41.15 |
| Support Level | $12.54 | $7.05 |
| Resistance Level | $12.64 | $8.24 |
| Average True Range (ATR) | 0.08 | 0.40 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 80.00 | 2.46 |
Price Performance
Historical ComparisonAbout PAI Western Asset Investment Grade Income Fund Inc.
Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. The company designed as a long-term investment and not as a trading vehicle. The fund seeks a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. Its portfolio is invested in securities which may be convertible into or exchangeable for, or carry warrants to purchase, common stock or other equity interests; and preferred stock.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.